tiprankstipranks
Syncona Shs GBP (GB:SYNC)
LSE:SYNC
UK Market

Syncona Shs GBP (SYNC) AI Stock Analysis

19 Followers

Top Page

GB:SYNC

Syncona Shs GBP

(LSE:SYNC)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 5.2)
Rating:55Neutral
Price Target:
96.00 p
▲(2.24% Upside)
Action:ReiteratedDate:12/30/25
The score is held back primarily by highly volatile and recently weak financial performance and negative technical momentum. Offsetting this are a conservatively positioned balance sheet (no debt) and positive corporate actions aimed at returning capital and improving shareholder value, but losses (negative P/E) keep the overall risk/quality profile mid-range.
Positive Factors
Conservative balance sheet (no debt)
Zero reported debt materially reduces financial risk and gives Syncona durable flexibility to fund follow-on investments, support portfolio companies through clinical cycles, and pursue buybacks or distributions without refinancing pressure. This strengthens resilience across biotech cycles.
Negative Factors
Earnings volatile and revaluation-driven
Reliance on fair-value changes for earnings creates persistent volatility and weak earnings visibility. For an investment company focused on biotech, this makes cashable returns lumpy, complicates forecasting, and limits reliable income for distributions or predictable NAV growth over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet (no debt)
Zero reported debt materially reduces financial risk and gives Syncona durable flexibility to fund follow-on investments, support portfolio companies through clinical cycles, and pursue buybacks or distributions without refinancing pressure. This strengthens resilience across biotech cycles.
Read all positive factors

Syncona Shs GBP (SYNC) vs. iShares MSCI United Kingdom ETF (EWC)

Syncona Shs GBP Business Overview & Revenue Model

Company Description
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest i...
How the Company Makes Money
Syncona makes money by investing in and managing a portfolio of life sciences companies. The company's revenue model primarily involves generating returns from its investments in these companies, either through exits such as public offerings or ac...

Syncona Shs GBP Financial Statement Overview

Summary
Balance sheet strength is a key positive (no debt and substantial equity), but the latest annual period saw a sharp deterioration with earnings turning deeply negative and multi-year profitability/cash flow remaining volatile, limiting overall quality and visibility.
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
55
Neutral
BreakdownTTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue64.35M-68.31M30.75M-39.79M18.69M78.54M
Gross Profit20.00M-68.31M14.10M-51.91M3.68M78.54M
EBITDA-74.69M-143.16M3.79M0.00-1.94M0.00
Net Income-93.58M-143.16M3.79M-56.02M8.84M53.16M
Balance Sheet
Total Assets1.03B1.06B1.25B1.27B1.33B1.34B
Cash, Cash Equivalents and Short-Term Investments213.00K1.11M261.00K11.00K276.00K14.00K
Total Debt0.000.000.000.000.000.00
Total Liabilities13.77M11.79M12.22M13.76M23.55M38.12M
Stockholders Equity1.02B1.05B1.24B1.25B1.31B1.30B
Cash Flow
Free Cash Flow5.88M0.0020.47M-265.00K262.00K-3.00K
Operating Cash Flow30.03M43.91M20.47M-265.00K262.00K-3.00K
Investing Cash Flow0.000.000.000.000.000.00
Financing Cash Flow-30.38M-43.06M-20.22M0.000.000.00

Syncona Shs GBP Technical Analysis

Technical Analysis Sentiment
Negative
Last Price93.90
Price Trends
50DMA
95.51
Negative
100DMA
96.00
Negative
200DMA
96.56
Negative
Market Momentum
MACD
-2.03
Positive
RSI
31.68
Neutral
STOCH
15.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNC, the sentiment is Negative. The current price of 93.9 is above the 20-day moving average (MA) of 91.97, below the 50-day MA of 95.51, and below the 200-day MA of 96.56, indicating a bearish trend. The MACD of -2.03 indicates Positive momentum. The RSI at 31.68 is Neutral, neither overbought nor oversold. The STOCH value of 15.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SYNC.

Syncona Shs GBP Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
£1.76B2.24%2.40%64.34%77.61%
72
Outperform
£1.42B4.1914.60%9.91%-28.89%-12.14%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
67
Neutral
£118.97M21.201.79%3.29%-9.37%
63
Neutral
£820.44M2.308.81%11.00%
55
Neutral
-5.91-12.49%-31.72%-404.64%
50
Neutral
£477.93M8.097.16%33.10%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:SYNC
Syncona Shs GBP
87.70
3.50
4.16%
GB:ASHM
Ashmore Group PLC
215.60
93.00
75.85%
GB:GROW
Molten Ventures
476.00
225.60
90.10%
GB:IPO
IP Group plc
54.10
17.00
45.82%
GB:MERC
Mercia Asset Management
28.00
5.21
22.86%
GB:CLDN
Caledonia Investments
341.00
1.80
0.53%

Syncona Shs GBP Corporate Events

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Syncona Wins Shareholder Backing for New Investment Policy and Board Refresh
Positive
Mar 3, 2026
Syncona shareholders have overwhelmingly approved a new investment policy and long-term incentive arrangements at a general meeting, with around 90 per cent of votes cast in favour of both resolutions. The changes signal a refreshed strategic and ...
Business Operations and StrategyProduct-Related Announcements
Syncona’s Quell Therapeutics Advances Lead CAR-Treg Autoimmune Therapy and Refocuses Pipeline
Positive
Mar 3, 2026
Syncona portfolio company Quell Therapeutics has begun a Phase I/II CHILL clinical trial of its lead autologous CAR-Treg therapy, QEL-005, in patients with rheumatoid arthritis and systemic sclerosis, following UK regulatory approval. Built on Que...
Business Operations and StrategyShareholder Meetings
Syncona Refines Investment Strategy and Incentives Ahead of Shareholder Vote
Positive
Feb 12, 2026
Syncona Limited has published a circular detailing a revised investment and capital allocation framework, as well as new long-term incentive arrangements for its investment manager, aimed at maximising shareholder value and creating a more sustain...
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
Syncona Posts Strong Q3 NAV Gains as Beacon Financing and Late‑Stage Pipeline Drive Outlook
Positive
Feb 5, 2026
Syncona reported a solid third quarter, with net assets rising to £1.06bn and NAV per share up 3.6% to 173.9p, driven by a 5% quarterly gain in its life sciences portfolio, notably a 20% uplift in Beacon Therapeutics following an oversubscrib...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 30, 2025